The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
